Dobutamine-atropine stress echocardiography and clinical data for predicting late cardiac events in patients with suspected coronary artery disease by Poldermans, D. (Don) et al.
Dobutamine-Atropine Stress Echocardiography and Clinical 
Data for Predicting Late Cardiac Events in Patients With 
Suspected Coronary Artery Disease 
Don Poldermans, MD, Paolo M. Fioretti, MD, FESC, Eric Boersma, BSE, Jan H. Cornel, MD, 
Filip Borst, MD, Erik G.J. Vermeulen, MD, Mariarosaria Arnese, MD, Abdou El-Hendy, MD, 
JOS R.T.C. Roelandt, MD, FACC, Rotterdam, The Netherlands 
PURPOSE: To compare the relative value of 
clinical variables with dobutamine-atropine stress 
echocardiography to predict cardiac events 
during long-term follow-up. Dobutamine stress 
echocardiography is increasingly used for the 
detection of coronary artery disease, but little is 
known of its prognostic value. 
PATIENTS AND METHODS: A total of 430 patients (310 
men; mean age 61 years, range 22 to 90) were 
enrolled in the study. Patients were referred for 
chest pain complaints and were unable to 
perform an adequate exercise stress test. All 
patients underwent dobutamine-atropine stress 
test (incremental dobutamine infusion: 10 to 40 
pg/kg/minute, continued with atropine 0.25 to 1 
mg intravenously if necessary to achieve 85% of 
the age predicted maximal heart rate, without 
symptoms or signs of ischemia) and clinical 
cardiac evaluation. Follow-up was 17 + 5 months, 
with a minimum of 6 months; 3 patients were lost 
to follow-up. Cardiac events were defined as 
cardiac death, nonfatal myocardial infarction, 
and coronary revascularization. 
RESULTS: Seventy-nine cardiac events occurred in 
76 patients: cardiac death (n = ll), nonfatal 
myocardial infarction (n = 18), and coronary 
revascularization (n q 50). By multivariate 
regression analysis, the prognostic value of the 
stress test in addition to common clinical 
variables was assessed. (1) Cardiac death was 
predicted by age greater than 70 years (odds 
ratio 5.6, 1.5 to 20) or new wall motion abnor- 
malities in a study that is normal at rest (odds 
ratio 4.1, 1.1 to 15). (2) Death or myocardial 
infarction was predicted by a history of myo- 
cardial infarction (odds ratio 4.8, 1.8 to 13) or 
age greater than 70 years (odds ratio 2.3, 1.1 to 
5.4), and the stress test outcome provided no 
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additional information. (3) If all events were 
combined, only stress test results were prog- 
nostic: new wall motion abnormalities in a study 
that is normal at rest (odds ratio 3.1, 1.9 to 5.1), 
wall motion abnormalities at rest (wall motion 
score at rest 2 1.12) (odds ratio 2.5, 1.4 to 4.0), 
or any new wall motion abnormalities during 
stress (odds ratio 2.0, 1.4 to 3.8). The positive 
predictive value of any new wall motion abnor- 
mality during stress for all late cardiac events 
was 25% (95% confidence interval [Cl] 19 to 31) 
with a negative predictive value of 87% (95% Cl 
83 to 91). 
CONCLUSION: In a large cohort of unselected 
patients with chest pain syndromes, new wall 
motion abnormalities induced by dobutamine 
provide additional information for late cardiac 
events, independent of clinical variables. 
I n patients with suspected coronary artery disease, numerous tests provide prognostic information for 
late cardiac events in addition to clinical data. These 
include ambulatory ST segment monitoring, l exercise 
electrocardiography,z,3 radionuclide ventriculogra- 
phy,4 thallium perfusion scintigraphy,5a6a7 and coro- 
nary angiography.8 Dobutamine-atropine stress com- 
bined with echocardiography has been recently 
proposed for the diagnosis of coronary artery disease 
by detection of ischemia-induced transient wall mo- 
tion abnormalities.g-13 Dobutamine has both positive 
inotropic and chronotropic effects on the heart by 
stimulating pl, p2, and al adrenoreceptors. The in- 
crease of myocardial oxygen demand might induce 
myocardial ischemia. The test is relatively inexpen- 
sive, widely available, independent of physical exer- 
cise capacity, safe,14 and provides diagnostic infor- 
mation for coronary artery disease.g A few recent 
studies15-l7 suggest that the test also has prognostic 
value, but only one full paper addresses this issue in 
a study on patients referred for chest pain. Prognostic 
information for late cardiac events may be valuable 
for risk stratification and the selection of patients for 
additional coronary angiography. Clinical variables 
are often insufficient due to latent coronary artery dis- 
ease, particularly in patients with limited exercise ca- 
pacity. Stress electrocardiographic testing provides 
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prognostic information for cardiac events, but it may 
have limitations for detecting residual ischemia in 
case of resting electrocardiographic (ECG) abnor- 
malities.” The aim of our study was to assess the rel- 
ative prognostic value of clinical variables and dobu- 
tamine-atropine stress echocardiography in 430 
patients referred for chest pain syndromes during 17 
months of follow-up. 
PATIENTS AND METHODS 
Patient Characteristics 
A total of 430 patients (310 men; age range 22 to 90 
years, mean 61 years) with known or suspected coro- 
nary artery disease were examined, from 1990 until 
1992 at the Thoraxcenter. All patients were referred 
for chest pain complaints (50% from the outpatient 
clinic). No patient had a recent infarction (less than 3 
months). Clinical data examined were age, sex, pre- 
vious infarction, angina pectoris, hypertension, smok- 
ing, cardiac arrhythmias, history of congestive heart 
failure, and medication use. A history of previous my- 
ocardial infarction was present in 207 patients, and 
typical angina pectoris in 238 patients. Both angina 
and previous infarction were present in 97 patients. 
Anti-anginal medication was continued during the 
study. A total of 212 patients were using B-blockers. 
The ECG at rest showed no abnormalities in 209 
(49%) of the cases, a previous myocardial infarction 
in 192 (45%), left ventricular hypertrophy in 10 (2.3%), 
left bundle branch block in 12 (2.7%), and right bun- 
dle branch block in 7 (1.6%). 
Dobutamine Stress Echocardiography 
The dobutamine-atropine stress echocardiography 
protocol was approved by the Hospital Ethics 
Committee and was performed as previously de- 
scribed.13 In short, after giving verbal informed con- 
sent, the patients underwent a resting two-dimen- 
sional precordial echocardiographic examination. 
Standard apical and parasternal views were recorded 
on video tape, and a 12-lead ECG was recorded. 
Dobutamine was then administered intravenously by 
infusion pump, starting at 10 pg/kg/minute for 3 min- 
Figure 1. The 14-segment model of the 
left ventricle. Lax = parasternal long 
axis; 4C = apical four chamber view; 
2C = apical two chamber view; inf = 
inferior; sept = septum; lat = lateral; 
ant = anterior. 
utes, increasing by 10 pg/kg/minute every 3 minutes 
to a maximum of 40 @/kg/minute (stage 4) and con- 
tinued for 6 minutes. In patients not achieving 85% of 
their age-predicted maximal heart rate who had no 
symptoms or signs of ischemia, atropine (starting 
with 0.25 mg increasing to a maximum of 1 mg) was 
given intravenously at the end of stage 4, while dobu- 
tamine was continued. Throughout dobutamine infu- 
sion, the ECG was continuously monitored, the 12- 
lead ECG was recorded each minute, and the blood 
pressure was measured by sphygmomanometry every 
3 minutes. The two-dimensional echocardiogram was 
continuously monitored and recorded on video tape 
during the final minute of each stage. Quad screen 
display for side-by-side examination of rest and stress 
images have become routine during the last 200 stud- 
ies. Metoprolol was available and used (1 to 5 mg in- 
travenously) to reverse the effects of dobutamine or 
dobutamine-atropine combination if these did not re- 
vert spontaneously and quickly. Atropine was used if 
bradycardia and hypotension occurred. Off-line as- 
sessment of echographic images was performed by 
two experienced investigators without knowledge of 
the patients’ clinical data but with knowledge of the 
doses of dobutamine and atropine used. When there 
was disagreement between the two investigators, a 
third one viewed the images without knowledge of 
the previous assessments, and a majority decision 
was achieved. For this semi-quantitative assessment, 
the left ventricular wall was divided into 14 segments 
(Figure l), and each was scored using a 4 point scale: 
1 = normal, 2 = hypokinetic, 3 = akinetic, 4 = dyski- 
netic.18 An increase in score between rest and stress 
in one or more segments constituted a positive test. 
All new wall motion abnormalities during stress, 
group I, were divided into three subgroups: group II 
= a new wall motion abnormality in a study that is 
normal at rest; group III = rest wall motion abnor- 
mality with remote ischemic response to stress; and 
group IV= worsening of pre-existing wall motion ab- 
normality during stress. 
Interruption criteria for the test were horizontal or 
downsloping ST depression of more than 2 mm at 80 
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msec after the J point, ST elevation, serious cardiac 
arrhythmias, significant chest pain, reduction in sys- 
tolic blood pressure to more than 40 mm Hg from that 
at rest, a systolic blood pressure of less than 90 mm 
Hg, hypertension (systolic blood pressure: greater 
than or equal to 220 mm Hg), or any side effect re- 
garded as being due to dobutamine. 
A new wall motion abnormality was considered as 
an interruption criteria only if it was severe and ex- 
tensive. As our experience grew, we were more ag- 
gressive in continuing the stress test until target heart 
rate was reached independent of mild new wall mo- 
tion abnormalities. We have previously shown excel- 
lent inter- and intra-observer reproducibility of inter- 
pretation of stress echocardiography of 91% and 92%, 
respectively.lg In addition, the reproducibility of wall 
motion abnormalities during dobutamine-atropine 
stress echocardiography was 100% in 23 patients who 
underwent two serial studies on different days.20 
Follow-Up 
Follow-up data were obtained over 17 + 5 months, 
with a minimum of 6 months. During follow-up, 
events defined as cardiac death, nonfatal myocardial 
infarction, ad coronary revascularization (bypass 
surgery or transluminal angioplasty) were collected. 
All cardiac events were assessed by physicians un- 
aware of patients former stress test results, by in- 
vestigation of hospital records, and correspondence 
with their general physician. 
Statistical Analysis 
Univariate analysis for categorial variables (clinical 
data [age, sex, previous infarction, angina pectoris, hy- 
pertension, cardiac arrhythmias, and anti-anginal med- 
ication] and stress test results [angina, ST segment 
changes, new wall motion abnormalities during stress, 
and rest wall motion abnormalities]) was performed 
using the &i-square test with Yates correction or 
Fisher’s exact test. Continuous variables were ana- 
lyzed using Student’s t-test, when appropriate. Kaplan- 
Meier curves were plotted to summarize follow-up 
data. To compare and visualize the predictive value of 
rest wall motion abnormalities, we used receiver op- 
erator characteristics curves (ROC curves) to find the 
best cut-off point. In these curves, the sensitivity ver- 
sus specificity of a test are plotted, in which sensitiv- 
ity is a fraction of positive classification for all patients 
who satisfy the endpoint criteria and specificity is the 
fraction of all negative classifications for all patients 
who satisfy the non-endpoint criteria. These curves 
provide a direct comparison of their results over the 
entire range of measurements. Stepwise logistic re- 
gression models were fitted to identify independent 
clinical predictors of late cardiac events and the ad- 
ditional prognostic value of stress test results. In the 
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TABLE I 
Side Effects During Dobutamine-Atropine Stress Test 
in 430 Patients 
Arrhythmias 
Paroxysmal atrial fibrillation 5 (1%) 
Nonsustained ventricular tachycardia 5 (1%) 
Ventricular fibrillation 1 (0.2%) 
Sustained ventricular tachycardia 1 (0.2%) 
Chills 11 (2.6%) 
Hypotension 220 to ~40 mm Hg 10 (2.3%) 
Hypotension 240 mm Hg 2 (0.5%) 
Hypotension = decrease systolic blood pressure compared to baseline. 
case of more than one event in the same patient, the 
worst cardiac event was considered for the analysis 
of the results. The difference in risk was expressed as 
the odds ratio (OR) with the corresponding 95% CIs. 
Differences were considered significant if the null hy- 
pothesis could be rejected at the 0.05 probability level. 
RESULTS 
Four hundred thirty-two patients were enrolled in 
the study. In two patients, no adequate echo images 
could be recorded. Both patients had severe pul- 
monary disease and were excluded from the study. 
In 430 patients, clinical data and stress test results 
were obtained. In 384 tests (89%), target heart rate was 
reached. In 46 (11%) examinations, the test was pre- 
maturely stopped because of severe chest pain in 23 
(5%); ECG changes in 10 (2%); echographic recorded 
new wall motion abnormalities in 2 (0.5%); severe hy- 
potension (systolic blood pressure decrease more 
than 40 mm Hg compared with baseline) in 2 (0.5%); 
cardiac arrhythmias in 6 (1.4%) (1 ventricular fibrilla- 
tion, 1 sustained ventricular tachycardia, and 4 parox- 
ysmal atrial fibrillation), and chills in 3 (0.7%). All side 
effects, though not always causing interruption of the 
test or occurring during recovery, are shown in Table 
I. Dobutamine dose used during test was 20 rag/kg/ 
minute in 7 patients, 30 pg in 42 patients, and 40 vg in 
381 patients. 
In 176 of 430 examinations, atropine was added in 
addition to the maximum dose of dobutamine. Atro- 
pine addition was more often used in patients on 
B-blocker medication (OR 4.9, 95% CI 3.1 to 7.7 in 
patients receiving versus those not receiving B-block- 
ers). Chest pain during stress occurred in 131 (30%) 
patients, and ST segment changes in 154 (36%). Any 
new wall motion abnormalities occurred in 182 (42%) 
patients (group I). Three subgroups were analyzed. In 
149 patients, there was a normal rest echocardiogram 
and ischemic response to stress (group II); in 31 pa- 
tients, there were rest wall motion abnormalities with 
remote ischemic response to stress (group III); and in 
39 patients, there was a worsening of pre-existing wall 
motion abnormalities (group IV). 
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TABLE II 
Association by Univariate Analysis of Clinical Data and Stress Test Results With Late Cardiac Events (N = 430) 
Cardiac Death Cardiac Death/infarction All Cardiac Events 
Age >70 years 5.1 (1.5-17) 2.3 (1.1-5.1) 1.6 (0.9-2.8) NS 
History of infarction 1.6 (0.5-5.5) NS 5.8 (1.9-20) 1.8 (0.9-2.4) NS 
History of angina 0.6 (0.2-2.2) NS 0.6 (0.3-1.3) NS 1.4 (0.7-1.9) NS 
Diabetes mellitus 0.5 (0.1-1.5) NS 0.5 (0.1-3.5) NS 0.3 (0.1-1.3) NS 
Anti-angina1 medication 0.5 (0.1-1.8) NS 0.7 (0.4-1.6) NS 1.2 (0.7-2.0) NS 
RWMA 1.5 (0.5-5.0) NS 2.9 (1.3-6.6) 2.7 (1.6-4.5) 
Angina during stress 1.1 (0.3-3.9) NS 1.9 (0.9-4.0) NS 1.5 (0.9-2.5) NS 
NWMA I 2.4 (0.7-8.4) NS 1.7 (0.8-3.6) NS 2.3 (1.4-3.8) 
NWMA II 3.5 (1.1-12) 2.2 (1.1-4.7) 3.0 (1.8-5.0) 
NWMA III 1.3 (0.2-11) NS 4.0 (1.5-11) 2.3 (1.5-11) 
NWMA IV 0.5 (0.2-3.1) NS 0.6 (0.4-5.0) NS 2.1 (066.9) NS 
Anti-angina1 medication = O-blockers and/or nitrates and/or calcium antagonists: RWMA = rest wall motion score index at rest 2 1.12; NWMA I = all new wall 
motion abnormalities; NWMA II = normal rest echo, ischemic response to stress; NWMA Ill = wall motion abnormalities at rest, remote ischemic response to 
stress; NWMA IV = worsening preexisting wall motion abnormalities to stress; NS = not significant. 
Side Effects 
Besides chest pain, hypotension and cardiac ar- 
rhythmias were the most important side effects of 
dobutamine-atropine stress test (Table I). There was 
no correlation between side effects and the addition 
of au-opine (odds ratio 0.7, 0.2 to 1.9). 
When hypotension was defined as a decrease of 
systolic blood pressure of more than 20 mm Hg 
compared with baseline, there were 12 incidents. 
Although most patients were able to continue the 
test without discomfort, in two patients the test 
was stopped because of severe and symptomatic 
hypotension (decrease of systolic blood pressure 
of more than 40 mm Hg). 
The occurrence of hypotension was not related to 
the dose of dobutamine, atropine addition, or induc- 
tion of ischemia. 
Significant and/or symptomatic cardiac arrhyth- 
mias occurred in 12 examinations: 1 patient devel- 
oped ventricular fibrillation, 1 patient sustained ven- 
tricular tachycardia, 5 patients experienced nonsus- 
tained ventricular tachycardia, and 5 patients had 
paroxysmal atrial fibrillation. The test was primar- 
ily stopped due to arrhythmias in six examinations. 
There were no deaths or myocardial infarctions. All 
patients who developed atrial fibrillation responded 
quickly to metoprolol intravenously, and one patient 
had digitalis as well. 
Follow-Up 
Three patients were lost to follow-up. Seventy- 
nine cardiac events occurred during follow-up in 
76 patients. Eleven patients experienced cardiac 
death, and 18 a nonfatal infarction. In 50 patients, 
a coronary revascularization was performed (by- 
pass surgery or a transluminal angioplasty). Seven 
patients had a stroke, and there were six noncar- 
disc deaths. 
The univariate analysis of clinical data and stress 
test results to predict cardiac death alone, cardiac 
death or myocardial infarction, and all cardiac events 
is presented in Table II. Cardiac death correlated 
with age greater than 70 years (odds ratio 5.1, 1.5 to 
17) and new wall motion abnormalities as in group II 
(odds ratio 3.5, 1.1 to 12); all other variables were not 
predictive. 
Cardiac death or myocardial infarction was related 
to a history of myocardial infarction (odds ratio 5.8, 
1.9 to 20), age greater than 70 years (odds ratio 2.3, 
1.1 to 5.1), new wall motion abnormalities as in group 
III (odds ratio 4.0, 1.5 to II), rest wall motion abnor- 
malities (wall motion score index at rest 2 1.12 was 
determined by ROC curves as best cut-off point) 
(odds ratio 2.9, 1.3 to 6.6), or new wall motion ab- 
normalities as in group II (odds ratio 2.2, 1.1 to 4.7). 
When cardiac events were combined, they were sig- 
nificantly correlated with new wall motion abnor- 
malities in group II (odds ratio 3.0, 1.8 to 5.0), rest 
wall motion abnormalities (wall motion score index 
at rest 2 1.12) (odds ratio 2.7, 1.6 to 4.5) and new wall 
motion abnormalities in groups I and III (odds ratio 
and 2.3, 1.4 to 3.8 and 2.3, 1.5 to 11, respectively) 
(Table II). The positive predictive value of any new 
wall motion response to stress for all late cardiac 
events was 25% (95% CI 19 to 31) and a negative pre- 
dictive value 87% (95% CI 83 to 91). 
Multivariate regression analysis was performed on 
all clinical variables and stress test results. Stress test 
results were analyzed for their additional prognostic 
value in addition to common clinical variables. There 
was a significant correlation between (1) cardiac 
death and age greater than 70 years (odds ratio 5.6, 
1.5 to 20) or new wall motion abnormalities in group 
II (odds ratio $1, 1.1 to 15), (2) cardiac death or my- 
ocardial infarction, and a history of a previous my- 
ocardial infarction (odds ratio 4.8, 1.8 to 13) or age 
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TABLE III 
Association by Multivariate Regression Analysis of Clinical Data and Stress Test Results 
With Late Cardiac Events (N = 430) 
Age >70 yrs 
ORTCI, 
RWMA NWMA I NWMA II NWMA Ill NWMA IV 
OR (Cl) OR (Cl) OR (Cl) OR (Cl) OR (Cl) OR (Cl) 
Cardiac death 5.6 (1.5-20) NS NS NS 4.1 (1.1-15) NS NS 
Cardiac death or 2.3 (1.1-5.4) 4.8 (1.8-13) NS NS NS NS NS 
myocardial infarction 
All events NS NS 2.5 (1.4-4.0) 2.0 (1.4-3.8) 3.1 (1.9-5.0) NS 2.3 (1.4-3.9) 
OR = odds ratio; Cl = 95% confidence interval; MI = history of previous myocardial infarction; RWMA = rest wall motion score index 2 1.12; 
NWMA I = all new all motion abnormalities; NWMA II = normal rest echo, ischemic response to stress; NWMA III = wall motion abnormalities at rest, 
remote ischemic response to stress; NWMA IV = worsening preexisting wall motion abnormalities to stress; NS = not significant. 
TABLE IV 
Events According to the Presence or Absence of a Previous Myocardial Infarction and of the Results of 
Dobutamine-Atropine Stress Echocardiography 
Myocardial Coronary 
Death Infarction Revasculariation No. of Events Total Events 
No previous MI (n = 223) 
DSE - (n = 147) 0 0 10 (7%) 137 (93%) 10 (7%) 
DSE + (n = 76) 3 (3.9%) 1 (1.3%) 13 (17%) 59 (76%) 17 (24%) 
Previous MI (n = 207) 
DSE - (n = 100) 4 (4%) 8 (8%) 9 (9%) 79 (78%) 21 (22%) 
DSE + (n = 107) 4 (3.7%) 9 (8%) 18 (17%) 76 (70%) 31 (30%) 
Ml = myocardial infarction; DSE = dobutamine-atropine stress echocardiography. 
greater than 70 years (odds ratio 2.3, 1.1 to 5.4), and 
(3) all cardiac events and new wall motion abnor- 
malities in group II (odds ratio 3.1, 1.9 to 5.0) rest 
wall motion abnormalities (wall motion score index 
at rest 2 1.12) (odds ratio 2.5, 1.4 to 4.0), or new wall 
motion abnormalities in group I (odds ratio 2.0, 1.4 to 
3.8)) (Table III). 
When patients with and without myocardial in- 
farction were compared (Table IV), there were more 
cardiac death and myocardial infarctions in the group 
with a previous myocardial infarction (P ~0.001). In 
147 patients without a previous myocardial infarction 
and a negative dobutamine-atropine stress test, no 
cardiac death or myocardial infarction occurred dur- 
ing follow-up of 17 months. Event-free survival curves 
for patients with and without new wall motion ab- 
normalities are presented in Figure 2A (endpoints 
were cardiac death and myocardial infarction) and 
Figure 2B (all cardiac events). For all cardiac events, 
there is a significant difference in event-free survival 
in patients with new wall motion abnormalities. 
COMMENTS 
Noninvasive risk stratification in patients with sus- 
pected or proven coronary artery disease is of in- 
creasing relevance, from one side to the rapid increase 
of the “therapeutic” modalities and on the other side 
to economic constraints we face. Pharmacologic 
stress echocardiography is a very promising tool in 
this context, since it is widely available and can be ap- 
plied in almost all patients and is less expensive than 
other imaging methods, like perfusion scintigraphy.21 
In this study, we tested the hypothesis that dobut- 
amine-atropine stress echocardiography provides su- 
perior information to clinical variables alone, to pre- 
dict the late clinical outcome in a cohort of 430 
patients referred for chest pain at one center. 
This is the largest study group so far that we know 
of with dobutamine-atropine stress echocardiography 
reported for this purpose. Further since, in our study 
dobutamine-atropine stress test was considered as a 
research tool, and the test outcome was not used for 
clinical management by the attending physicians, a 
referral bias for coronary arteriography and subse- 
quent revascularization has been avoided. 
Our data show that new wall motion abnormalities 
during dobutamine-atropine stress echocardiography 
provide additional prognostic information in addition 
to clinical variables, when cardiac death and all car- 
diac events were considered. As expected, elderly age 
(greater than 70 years) was the strongest predictor of 
cardiac death, while new wall motion abnormalities 
during stress with a normal rest echocardiogram pro- 
vided additional prognostic information. When non- 
fatal infarction was added to death as an endpoint, 
the predictive power of echo parameters were lost. 
This is consistent with the lack of predictive value for 
nonfatal infarction of any stress testz2 and can be ex- 
plained by a sudden progression, like a plaque rup- 
ture of a moderate lesion that is often undetected by 
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Figure 2. Kaplan-Meier curves for cardiac death and myocardial infarction (A) and all events (B) during follow-up by results of dobutamine- 
atropine stress test (with or without new wall motion abnormalities). Each plot represents the cumulative percentage of patients remaining 
events free. Vertical lines representing 95% confidence interval. For all cardiac events, there is a significant difference in event-free survival 
in patients with new wall motion abnormalities. 
the stress test. Common clinical variables such as a 
previous infarction and elderly age were predictive 
for cardiac death or nonfatal infarction. 
If all cardiac events were combined, only stress test 
results provided independent information for late 
events. Stress echocardiographic results were most 
predictive of subsequent events in patients with nor- 
mal wall motion at rest and an ischemic response to 
stress (group II). In contrast, the results were not pre- 
dictive (group III) or less predictive (group IV) in the 
presence of abnormal wall motion at rest. This is not 
surprising, considering that the interpretation of stress 
echocardiography is most difficult in patients with ab- 
normal wall motions at rest. This is particularly true 
in patients with akinetic segments becoming dyski- 
netic during stress. We have recently demonstrated, 
using perfusion scintigraphy as a reference method, 
that this pattern is not consistent with ischemia.“3 
Most importantly, echocardiographic results pro- 
vided additional information beyond clinical data 
alone. In patients referred for chest pain complaints 
without a previous myocardial infarction, a negative 
stress test is associated with a low risk for cardiac 
death or myocardial infarction. 
One study presented as a full paper and two ab- 
stracts have addressed th? prognostic value of dobu- 
tamine stress echocardiography. Unfortunately, the 
study of Mazeika et alI5 is difficult to compare with 
our study. The population studied consisted of 
younger patients (54 + 9 versus 61 f 8 years), mostly 
with typical angina, (78% versus 55%) and of limited 
number (51 versus 430). During follow-up, only one 
patient had a myocardial infarction, and there were 
no cardiac deaths. Thus, their endpoints consisted 
mainly of recurrent angina, and they found a positive 
predictive value of 78% and a 95% CI of 62 to 94. This 
is higher than what we found for all cardiac events of 
25% and 95% CI of 19 to 31, but this cam be due to the 
very different study group. Also, these authors did not 
specify to what extent the results of the test were used 
for subsequent therapeutic interventions, which were 
considered as endpoints. It is important to underscore 
again that in our study the attending physicians were 
blinded to the results of the test. The negative pre- 
dictive value was comparable, 78%, 95% CI 62 to 94 in 
the study by Mazeika et aJ15 versus 87%, 95% CI 83 to 
91 in our study. 
Two other studies are published in abstract form. 
The study of Marcovitz et all6 consists of 291 patients 
with a comparable follow-up of 15 + 4 months and 18 
cardiac deaths and 16 myocardial infarctions. Patients 
with rest wall motion abnormalities (176 versus 291 
have a higher incidence of cardiac death compared 
with patients without resting wall motion abnormal- 
ities (16 versus 2, respectively). In patients with a neg- 
ative test and no rest wall motion abnormalities (76 
of 291), no cardiac death and only 1 myocardial in- 
farction occurred. This is in perfect agreement with 
our findings. The study of Kamran et all7 consists of 
207 patients with a shorter follow up of 9 + 5.7 
months. This study showed by multivariate regression 
analysis the predictive value of new wall motion ab- 
normalities during stress for cardiac death, although 
these patients were also assessed for perioperative 
risk, which might have created a bias. 
Dipyridamole echocardiography has also been 
used for prognostic stratification. The study of Picano 
et al24 shows similar results to ours with positive pre- 
dictive value of 36% and a 95% CI of 30 to 42 and a 
negative predictive value of 94% and a 95% CI of 91 
to 97 for late cardiac events. Dipyridamole thallium 
scintigraphy has also been used for prognostic eval- 
uation in patients referred for complaints of chest 
pain7 The predictive value for cardiac death or non- 
fatal infarction is comparable only if new wall motion 
abnormalities in group II (with normal rest and the 
ischemic response to stress) are considered. Positive 
predictive value in our study is 10% with a 95% CI of 
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5 to 15 versus 14% and a 95% CI of 10 to 18 in the 
study of Hendel et al7 Both studies show a high neg- 
ative predictive value of 95% with a 95% CI of 92 to 
98 versus 96% with a 95% CI of 93 to 99. However, no 
head-to-head comparison between dipyridamole and 
dobutamine has been done for risk stratification. 
Therefore, it is unclear which stress modality should 
be preferred. 
CONCLUSIONS 
In summary, in the present study we found that 
dobutamine-atropine stress echocardiography ap- 
plied in patients referred for chest pain complaints 
identifies a large proportion of patients with an ex- 
cellent prognosis if the test is normal. In case of stress 
induced new wall motion abnormalities, the risk for 
late cardiac events, and especially cardiac death or 
coronary revascularisation, is increased. 
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